学术探索
学术期刊
学术作者
新闻热点
数据分析
智能评审

Clinical Utility of Serum Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-2 Concentrations in the Assessment of Liver Fibrosis due to Chronic Hepatitis B

被引：13
作者：
Liang, B. [1 ]
Li, Y. [3 ]
Zhao, A. [1 ]
Xie, F. [1 ]
Guo, Z. [1 ,2 ]
机构：
[1] China Med Univ, High Vocat Technol Coll, Shenyang 110001, Peoples R China
[2] China Med Univ, Dept Pharmaceut Toxicol, Shenyang 110001, Peoples R China
[3] 202 Hosp, Dept Lab Med, Shenyang, Peoples R China
来源：
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH | 2012年 / 40卷 / 02期
关键词：
HEPATITIS B; LIVER FIBROSIS; MATRIX METALLOPROTEINASE-2 (MMP-2); TISSUE INHIBITOR OF METALLOPROTEINASE-2 (TIMP-2); FIBROTIC HUMAN LIVER; NONINVASIVE MARKERS; BIOPSY; EXPRESSION; DIAGNOSIS; DISEASES; TIMP-1; MMP-2; MANAGEMENT; RAT;
D O I：
10.1177/147323001204000225
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
100103 [病原生物学]; 100218 [急诊医学];
摘要：
OBJECTIVE: To explore the relationships between serum concentrations of tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 (MMP-2), and severity of liver fibrosis in chronic hepatitis B. METHODS: A total of 101 patients with hepatitis B and 54 healthy control subjects were consecutively enrolled. Serum MMP-2 and TIMP-2 were quantified by enzyme-linked immunosorbent assay. RESULTS: Serum MMP-2 concentrations in patients with stage F2 - F4 fibrosis were significantly higher than in patients with stage F0 - F1 fibrosis and control subjects, but no significant difference was found between patients with stage F0 - F1 fibrosis and control subjects. Significant differences in serum TIMP-2 concentrations were found between patients with stages F2 - F4 and F0 - F1 fibrosis, and between stages F0 - F1 fibrosis and healthy control subjects. Areas under the receiver operating characteristic curves of serum TIMP-2 and MMP-2 for predicting clinically significant fibrosis (stage F2 - F4) were 0.899 and 0.770, respectively. CONCLUSION: Serum TIMP-2 and MMP-2 assessment may represent a valuable noninvasive diagnostic test for liver fibrosis in hepatitis B.
引用
收藏
页码：631 / 639
页数：9
相关论文
共 37 条
[1]
Biopsy or biomarkers: Is there a gold standard for diagnosis of liver fibrosis? [J].
Afdhal, NH .
CLINICAL CHEMISTRY, 2004, 50 (08) :1299-1300
[2]
Evaluation of liver fibrosis: A concise review [J].
Afdhal, NH ;
Nunes, D .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (06) :1160-1174
[3]
ARTHUR MJP, 1995, J HEPATOL, V22, P43
[4]
Non-Invasive markers for hepatic fibrosis [J].
Baranova, Ancha ;
Lal, Priyanka ;
Birerdinc, Aybike ;
Younossi, Zobair M. .
BMC GASTROENTEROLOGY, 2011, 11
[5]
Liver fibrogenesis:: A new role for the renin-angiotensin system [J].
Bataller, R ;
Sancho-Bru, P ;
Ginès, P ;
Brenner, DA .
ANTIOXIDANTS & REDOX SIGNALING, 2005, 7 (9-10) :1346-1355
[6]
Sampling variability of liver fibrosis in chronic hepatitis C [J].
Bedossa, P ;
Dargère, D ;
Paradis, V .
HEPATOLOGY, 2003, 38 (06) :1449-1457
[7]
Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver [J].
Benyon, RC ;
Iredale, JP ;
Goddard, S ;
Winwood, PJ ;
Arthur, MJP .
GASTROENTEROLOGY, 1996, 110 (03) :821-831
[8]
Progelatinase A is produced and activated by rat hepatic stellate cells and promotes their proliferation [J].
Benyon, RC ;
Hovell, CJ ;
Da Gaça, M ;
Jones, EH ;
Iredale, JP ;
Arthur, MJP .
HEPATOLOGY, 1999, 30 (04) :977-986
[9]
Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C [J].
Boeker, KHW ;
Haberkorn, CI ;
Michels, D ;
Flemming, P ;
Manns, MP ;
Lichtinghagen, R .
CLINICA CHIMICA ACTA, 2002, 316 (1-2) :71-81
[10]
Common reference intervals for aspartate aminotransferase (AST), alanine aminotransferase (ALT) and γ-glutamyl transferase (GGT) in serum: results from an IFCC multicenter study [J].
Ceriotti, Ferruccio ;
Henny, Joseph ;
Queralto, Josep ;
Ziyu, Shen ;
Ozarda, Yesim ;
Chen, Baorong ;
Boyd, James C. ;
Panteghini, Mauro .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2010, 48 (11) :1593-1601
1234